Drugs / JT-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05296044 | Apr 2022 → Oct 2023 | type 2 diabetes mellitus | Jeil Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JT-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05296044 ↗ |